Savolitinib

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.[2] It has been given conditional approval for these indication in China.[3]

Savolitinib
Clinical data
Other namesVolitinib
Identifiers
IUPAC name
  • 3-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
CAS Number
ChemSpider
UNII
KEGG
ECHA InfoCard100.238.920
Chemical and physical data
FormulaC17H15N9
Molar mass345.370 g·mol−1
3D model (JSmol)
SMILES
  • C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21
InChI
  • InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1
  • Key:XYDNMOZJKOGZLS-NSHDSACASA-N

References
  1. "Savolitinib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016.
  2. "Savolitinib - AstraZeneca/Hutchison China MediTech Limited". AdisInsight. Springer Nature Switzerland AG.
  3. Markham A (September 2021). "Savolitinib: First Approval". Drugs. 81 (14): 1665–1670. doi:10.1007/s40265-021-01584-0. PMID 34455538.
  • "Savolitinib". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.